Navigation Links
Drug Shows Promise in Nervous-System Tumor Treatment
Date:7/8/2009

In small study, some patients had their hearing restored

WEDNESDAY, July 8 (HealthDay News) -- U.S. researchers report the first successful drug treatment of tumors in patients with neurofibromatosis type 2 (NF2).

In people with NF2, benign tumors develop throughout the nervous system. The most common tumor is a vestibular schwannoma, which grows on the nerve connecting the ear to the brain. This type of tumor, also called acoustic neuroma, causes hearing loss and can press on the brain stem, leading to serious neurologic symptoms and the risk of death.

Currently, these tumors are treated with surgery or radiation. This study found that treatment with the angiogenesis inhibitor bevacizumab (Avastin) shrank vestibular schwannomas, improved hearing and eased other symptoms in NF2 patients.

Bevacizumab is an anti-cancer drug designed to reduce blood flow to tumors in order to shrink them. But the drug wasn't used on acoustic neuromas because it was believed that they didn't stimulate formation of new blood vessels, as malignant tumors do.

But researchers at Massachusetts General Hospital in Boston analyzed tissue samples of NF2-related vestibular schwannomas and found evidence of excess blood vessel development. They then decided to test bevacizumab in 10 NF2 patients with vestibular schwannomas.

Tumor shrinkage occurred in nine patients, six of whom had a 20 percent or greater reduction in tumor size. The tumor shrinkage lasted between 11 and 16 months. Of the seven patients who had started to lose their hearing before treatment, four had some hearing restored. This improvement also lasted for up to 16 months.

"This kind of treatment response is unprecedented," lead author Dr. Scott Plotkin of the Pappas Center for Neuro-Oncology in the MGH Cancer Center, said in a news release. "Our study is the first to provide evidence that a drug can shrink vestibular schwannomas…and the first
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Study shows endoscopic surgery as effective open surgery for nasal cancer
2. Independent Laboratory Testing Shows BioNeutrals Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
3. CU-Boulder study shows brains immune system may cause chronic seizures
4. New Study Shows Daily Sex Can Increase Sperm Count
5. Study shows PET can measure effectiveness of novel breast cancer treatment
6. New Study Shows Many Unplanned Quit Smoking Attempts are Successful
7. Police work undermines cardiovascular health, comparison to general population shows
8. Study shows 1 in 25 deaths worldwide attributable to alcohol
9. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
10. Girls Overall Self-Worth Improves With Contact Lens Wear, Study Shows
11. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Shows Promise in Nervous-System Tumor Treatment 
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... (HealthDay News) -- The tragic death from "rat-bite fever" of ... the pet rodents, according to a report from the U.S. ... a rare but potentially fatal illness that should be considered ... a history of rodent exposure is reported," said a team ... Service. The case outlined in the report occurred in ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... BRUNSWICK, N.J. Researchers at Rutgers Ernest Mario School ... the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory ... the transition of early prostate cancer to its more ... is the second leading cause of cancer death in ...
... Cancer Center at Thomas Jefferson University in Philadelphia ... pressure medications might help prevent the spread of ... that one type of pressure-lowering drug called an ... and causes cell death. , In earlier work ...
... discovered evidence that a series of genetic mutations work ... often-fatal form of acute lymphoblastic leukemia (ALL). , These ... of a gene, IKZF1, whose protein, Ikaros, normally helps ... a lymphocyte. The researchers also found that loss of ...
... Patented OwnCode(R) Consumer Heart Rate Monitor Technology Now Available in ... ... 2008 Polar, the leader in,heart rate monitoring and fitness ... only available in,Polar heart rate monitors -- can now be ...
... Calif., April 14 HealthFusion, a,national ... recognized for,call center operation customer satisfaction ... Certified Call Center Program(SM). This distinction,acknowledges ... call center,operations to provide "An Outstanding ...
... Galien USA 2008 Announced for September 24, Nominations ... Nobel Laureate Walter,Gilbert, Ph.D., the Carl M. Loeb ... Biogen, has joined fellow Nobel Laureates on the,committee ... research. Prix Galien USA 2008,( http://www.prix-galien-usa.com ) will ...
Cached Medicine News:Health News:Celebrex-Lipitor combo may halt prostate cancer 2Health News:Celebrex-Lipitor combo may halt prostate cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 3Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2